The FDA issued recommendations for a BLA submission regarding a global Phase 3 study conducted by Larimar Therapeutics, utilizing the START pilot program.
4 reports, 2 independent
Updated Jul 3
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA issued recommendations for a BLA submission regarding a global Phase 3 study conducted by Larimar Therapeutics, utilizing the START pilot program.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Start
Nothing else this week.
-
Europe
terrestrial continent located in north-western Eurasia
- U.K.
Related events
- Abivax SA, a French company, is conducting clinical trials in the US and seeking alignment on NDA submission strategy with the FDA.
- The FDA is reviewing the Biologics License Application (BLA) submission from Capricor Therapeutics regarding its therapeutics for Duchenne Muscular Dystrophy (DMD).
- The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.
Coverage
Newest first; wire copies grouped- yahoo.com
- finanznachrichten.de
- Unknown outlet